Action Amgen - AMGN

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Me

Denosumab Trial Met Primary and All Secondary Endpoints by Significantly Delaying Time to First Skeletal Related Event and Significantly Reducing...

Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share

Fourth Quarter 2009 Revenue Increased 2 Percent to $3.8 Billion; Full Year 2009 Revenue Decreased 2 Percent to $14.6 Billion Fourth Quarter 2009...

Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium

THOUSAND OAKS, Calif., Jan. 21 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that detailed results from two pivotal Phase 3...

Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results

THOUSAND OAKS, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that it plans to report its fourth quarter and...

Amgen Donates $2 Million, Establishes Earthquake Relief Program

Company, Staff Contributions To Help Haitian Victims THOUSAND OAKS, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today...

Amgen to Present at the 28th Annual JP Morgan Healthcare Conference

THOUSAND OAKS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) will present at the 28th Annual JP Morgan Global Healthcare...

Amgen Resolves EPO Patent Dispute With Roche

Roche Admits Infringement And Validity Of Amgen's EPO Patents; Court Enters Permanent Injunction; Amgen Allows Roche's MIRCERA Onto U.S. Market In...

Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines

THOUSAND OAKS, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) announced today that Roger M. Perlmutter, M.D., Ph. D., Amgen's...

Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program

THOUSAND OAKS, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that its board of directors has authorized...

New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists

Applications for 2010 Amgen Scholars U.S. and Europe Programs Now Available THOUSAND OAKS, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Each year...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

AMGN - Frequently Asked Questions (FAQ)

What is the current Amgen share price?

The current share price of Amgen is 0,00 €

What is the 1 year trading range for Amgen share price?

Amgen has traded in the range of 0,00 € to 0,00 € during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
1WECWEC Energy Group Inc	106,10 € (13,02%)	4
NEXINexi S.p.A.	5,112 € (10,12%)	13,04M
GROWGrowens Spa	3,88 € (7,78%)	27,86k
WS3D25Solid World Group spa	0,09 € (6,51%)	51,13k
WSGC28SG Company SpA	0,0305 € (5,90%)	100k
1FRVIAForvia SE	8,712 € (-19,93%)	256,15k
WABTGAlfio Bardolla Training Group Spa	0,093 € (-15,45%)	40,75k
EPHEPH SpA	0,045 € (-14,29%)	42,74k
WELESEles Spa	0,09 € (-14,04%)	50k
1VARVarta AG	1,39 € (-11,75%)	17,3k
TITTelecom Italia SpA	0,2698 € (0,26%)	39,27M
SPMSaipem Spa	2,27 € (0,93%)	18,67M
ISPIntesa Sanpaolo Spa	4,716 € (-0,77%)	18,22M
NEXINexi S.p.A.	5,108 € (10,04%)	13,04M
ENELEnel Spa	7,032 € (0,64%)	6,6M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Amgen Inc (AMGN)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

AMGN Dernières nouvelles

Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Me

Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share

Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium

Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results

Amgen Donates $2 Million, Establishes Earthquake Relief Program

Amgen to Present at the 28th Annual JP Morgan Healthcare Conference

Amgen Resolves EPO Patent Dispute With Roche

Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines

Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program

New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists

AMGN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Amgen Inc (AMGN) Cours

Amgen Inc (AMGN)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

AMGN Dernières nouvelles

Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Me

Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share

Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium

Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results

Amgen Donates $2 Million, Establishes Earthquake Relief Program

Amgen to Present at the 28th Annual JP Morgan Healthcare Conference

Amgen Resolves EPO Patent Dispute With Roche

Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines

Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program

New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists

AMGN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE